Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 Y220C |
| Therapy | Rezatapopt |
| Indication/Tumor Type | ureter squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 Y220C | ureter squamous cell carcinoma | predicted - sensitive | Rezatapopt | Case Reports/Case Series | Actionable | In a Phase I/II trial (PYNNACL), Rezatapopt (PC14586) treatment resulted in rapid clinical symptom improvement and radiographic stable disease lasting 6 months in a patient with metastatic squamous cell carcinoma of the ureter harboring TP53 Y220C (PMID: 41504628; NCT04585750). | 41504628 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41504628) | Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators. | Full reference... |